Table 1.
Baseline characteristics of included patients
| Variable | Cognitive impairment on Day 30 | All (n = 207) | P value | |
|---|---|---|---|---|
| Without (n = 171) | With (n = 36) | |||
| Age (y) | 51.5 ± 20.4 | 56.2 ± 15.8 | 54.7 ± 18.3 | 0.322 |
| Gender (M/F) | 96/75 | 22/14 | 118/89 | 0.584 |
| Time from poisoning to treatment (h) | 4.8 (2.0‐6.9) | 4.1 (1.6‐7.0) | 4.5 (2.2‐6.5) | 0.632 |
| Body temperature (°C) | 36.4 ± 0.7 | 37.0 ± 0.5 | 36.9 ± 0.6 | 0.173 |
| Heart rate (beats/min) | 81.4 ± 16.9 | 88.7 ± 22.6 | 85.3 ± 21.4 | 0.115 |
| Respiratory rate (respirations/min) | 16.4 ± 3.8 | 19.0 ± 4.9 | 18.2 ± 4.0 | 0.344 |
| Mean arterial pressure (mm Hg) | 90.2 ± 18.6 | 84.4 ± 26.2 | 87.3 ± 20.1 | 0.131 |
| APACHE II score | 18.03 ± 6.65 | 29.74 ± 7.08 | 24.32 ± 6.86 | <0.001 |
| Serum cholinesterase level (U/L) | 680.5 (247.0‐1747.5) | 325.0 (130.5‐725.0) | 549.0 (197.5‐1146.0) | 0.116 |
| Serum cholinesterase activity (%) | 15.12 (5.49‐38.83) | 7.22 (2.9‐16.11) | 12.2 (4.39‐25.47) | 0.116 |
| Lactate (mmol/L) | 2.65 (0.44‐4.82) | 4.35 (2.52‐6.23) | 3.42 (1.37‐5.40) | 0.010 |
| pH | 7.32 ± 0.18 | 7.27 ± 0.10 | 7.30 ± 0.15 | 0.142 |
| level (mmol/L) | 18.44 ± 5.47 | 17.53 ± 6.45 | 18.02 ± 5.97 | 0.437 |
| White blood cell (×109/L) | 9.35 (3.73‐14.05) | 14.96 (8.06‐19.32) | 12.15 (6.35‐17.08) | 0.008 |
| C‐reactive protein level (mg/L) | 20.80 ± 9.21 | 24.72 ± 7.84 | 22.57 ± 8.18 | 0.107 |
| Serum UCH‐L1Day1 levels | 4.25 (2.57‐6.31) | 8.51 (6.53‐10.22) | 5.13 (2.92‐7.54) | <0.001 |
| Duration of ICU (h) | 5.15 (3.10‐7.15) | 5.75 (2.95‐8.60) | 5.60 (2.60‐8.05) | 0.709 |
| Mechanical ventilation time (h) | 3.55 (1.05‐6.10) | 4.80 (0.85‐8.35) | 4.05 (0.50‐7.25) | 0.334 |
Numerical variables are presented as mean ± standard deviation (SD) or median (interquartile range) and were analyzed using the unpaired Student's t test or Mann‐Whitney U test. Categorical variables are expressed as counts and were analyzed using the chi‐square test.
Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; UCH‐L1, ubiquitin C‐terminal hydrolase L1.